Moleculin Biotech Inc MBRX

NAS: MBRX | ISIN: US60855D1019   10/05/2024
4,760 USD (-0,42%)
(-0,42%)   10/05/2024

9 mei 2024 · Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin · Persbericht

8 mei 2024 · Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast · Persbericht

7 mei 2024 · Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data · Persbericht

2 mei 2024 · Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 · Persbericht

1 mei 2024 · Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin · Persbericht

18 april 2024 · European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) · Persbericht

10 april 2024 · Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties · Persbericht

28 maart 2024 · Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference · Persbericht

27 maart 2024 · Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity · Persbericht

27 maart 2024 · Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML · Persbericht

25 maart 2024 · Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial · Persbericht

22 maart 2024 · Moleculin Reports Full Year 2023 Financial Results · Persbericht

20 maart 2024 · Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast · Persbericht

19 maart 2024 · Moleculin Announces Reverse Stock Split · Persbericht

12 maart 2024 · Moleculin to Present at the 36th Annual ROTH Conference · Persbericht

24 januari 2024 · Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 · Persbericht

21 december 2023 · Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market · Persbericht

11 december 2023 · Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting · Persbericht

13 november 2023 · Moleculin Reports Third Quarter 2023 Financial Results · Persbericht

7 november 2023 · Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast · Persbericht

Mijn selecties